Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2022 | Outperform → Market Perform | William Blair | |
| 2/2/2022 | $16.00 → $6.00 | Hold | Chardan Capital |
| 12/23/2021 | $20.00 → $16.00 | Buy | Chardan Capital |
| 11/17/2021 | $24.00 → $8.00 | Overweight | Barclays |
| 11/16/2021 | $17.00 → $16.00 | Market Outperform | JMP Securities |
SC 13G/A - ContextLogic Inc. (0001822250) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
10-Q - ContextLogic Inc. (0001822250) (Filer)
8-K - ContextLogic Inc. (0001822250) (Filer)
8-K - ContextLogic Inc. (0001822250) (Filer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management. Ms. Paul and Ms. Olson are both seasoned industry experts with extensive experience in the pharmaceutical and biotechnology industries including in the gene therapy and rare disease sectors. "It is an exciting time at LogicBio with ongoing efforts to expand the reach of our G
William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously
OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and nine months ended September 30, 2024. Third Quarter 2024 Financial Highlights Net Loss: Net loss was $1 million, compared to a net loss of $80 million in the third quarter of 2023.As of September 30, 2024, the Company had $33 million in cash and cash equivalents, $117 million in marketable securities and $8 million in prepaid expenses and other current assets (primarily made up of $7 million in restricted cash). Company Outlook Over the last quarter, the Company has created a streamlined administrat
OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2024. Company Update On February 10, 2024, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Qoo10 Inc., a Delaware corporation ("Qoo10 Delaware"), and, for certain specified purposes, Qoo10 Pte. Ltd., a Singapore private limited company and Qoo10 Delaware's parent company ("Qoo10"), pursuant to which (i) the Company agreed to sell substantially all of its assets to Qoo10 Delaware or an affiliate designated by Qoo10 Delaware (such desig
As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact
As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact
Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country. The rare diseases market was valued at
Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country. The rare diseases market was valued a
Gainers JX Luxventure (NASDAQ:JXJT) shares increased by 13.3% to $1.7 during Thursday's regular session. The market value of their outstanding shares is at $10.3 million. Koss (NASDAQ:KOSS) shares increased by 9.59% to $11.65. The company's market cap stands at $107.8 million. Greenlane Hldgs (NASDAQ:GNLN) stock rose 7.27% to $0.29. The company's market cap stands at $1.1 million. Kirkland's (NASDAQ:KIRK) shares rose 4.99% to $1.68. The market value of their outstanding shares is at $21.9 million. Rent the Runway (NASDAQ:RENT) stock increased by 4.95% to $15.46. The company's market cap stands at $57.5 million. Losers ToughBuilt Industries (NASDAQ:TBLT) stock fell 10.8% to $4.47 duri
LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losses of $(0.31) per share from the same period last year.
On Friday, shares of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) experienced volatile short activity. After the activity, the stock price went up +0% to $2.07. The overall sentiment for LOGC has been Neutral. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 11/4/2022 with a volatility change of +102.26%. The current volatility indicator stands at 7.928. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers.